Source link : https://www.newshealth.biz/health-news/treatment-of-smoldering-myeloma-cuts-progression-rate-in-half/
SAN DIEGO — The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), according to a study reported here. The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific treatment to 63.1% with a […]
Author : News Health
Publish date : 2024-12-09 16:02:06
Copyright for syndicated content belongs to the linked Source.